ARROWHEAD PHARMACEUTICALS, INC.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

ARWR$49.00-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands)

CommonStock · Amount ($) · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Common Stock in Treasury · Treasury Amount ($) · Non-controlling Interest · Total
Balance at September 30, 2025	138,363	$231	$2,139,725	$6,443	$(1,627,154)		(2,661)		$(53,193)		$37,364		$503,416
Stock-based compensation	—	—	19,371	—	—		—		—		—		19,371
Exercise of stock options	296	—	5,098	—	—		—		—		—		5,098
Common stock - restricted stock units vesting	704	1	1	—	—		—		—		—		2
Issuance of common stock under at-the-market offering, net of issuance costs	689	1	46,831	—	—		—		—		—		46,832
Foreign currency translation adjustments	—	—	—	110	—		—		—		—		110
Unrealized gains on available-for-sale securities, net	—	—	—	146	—		—		—		—		146
Dividends declared by variable interest entity to noncontrolling shareholders	—	—	—	—	—		—		—		(40,520)		(40,520)
Net income (loss)	—	—	—	—	30,811		—		—		(2,569)		28,242
Balance at December 31, 2025	140,052	$233	$2,211,026	$6,699	$(1,596,343)		(2,661)		$(53,193)		$(5,725)		$562,697
Stock-based compensation	—	—	16,670	—	—		—		—		—		16,670
Exercise of stock options	121	—	1,968	—	—		—		—		—		1,968
Common stock - restricted stock units vesting	1,043	1	—	—	—		—		—		—		1
Issuance of common stock in follow-on offering, net of issuance costs	2,016	2	116,605	—	—		—		—		—		116,607
Issuance of pre-funded warrants	—	—	99,998	—	—		—		—		—		99,998
Purchase of Capped Calls related to the 2026 Convertible Note	—	—	(47,880)	—	—		—		—		—		(47,880)
Foreign currency translation adjustments	—	—	—	990		—		—		—		990
Unrealized losses on available-for-sales securities	—	—	—	(6,934)		—		—		—		(6,934)
Change in ownership interest in consolidated VIE	—	—	(3,120)	(13)	—		—		—		3,133		—
Gain on VIE's sale of IPR&D assets	—	—	—	—	—		—		—		(7,629)		(7,629)
Net loss	—	—	—	—	(132,732)		—		—		(4,840)		(137,572)
Balance at March 31, 2026	143,232	$236	$2,395,267	$742	$(1,729,075)		(2,661)		$(53,193)		$(15,061)		$598,916
Stock-based compensation	—	—	14,872	—	—		—		—		—		14,872
Exercise of stock options	149	—	5,697	—	—		—		—		—		5,697
Common stock - restricted stock units vesting	48	—	—	—	—		—		—		—		—
Issuance of common stock under at-the-market offering, net of issuance costs	367	1	27,238	—	—		—		—		—		27,239
Foreign currency translation adjustments	—	—	—	278	—		—		—		209		487
Unrealized losses on available-for-sales securities	—	—	—	(2,254)	—		—		—		—		(2,254)
Net (loss) income	—	—	—	—	(194,280)		—		—		15,364		(178,916)
Balance at June 30, 2026	143,796	$237	$2,443,074	$(1,234)	$(1,923,355)		(2,661)		$(53,193)		$512		$466,041

	CommonStock	Amount ($)	AdditionalPaid-InCapital	Accumulated Other Comprehensive Income	AccumulatedDeficit	Common Stock in Treasury	Treasury Amount ($)	Non-controlling Interest	Total
Balance at September 30, 2024	124,376	$217	$1,806,000	$4,750	$(1,625,523)	—	$—	$5,619	$191,063
Stock-based compensation	—	—	15,209	—	—	—	—	—	15,209
Exercise of stock options	70	—	634	—	—	—	—	—	634
Common stock - restricted stock units vesting	209	—	—	—	—	—	—	—	—
Issuance of pre-funded warrants	—	—	25,000	—	—	—	—	—	25,000
Foreign currency translation adjustments	—	—	—	(106)	—	—	—	—	(106)
Unrealized losses on available-for-sale securities, net	—	—	—	(507)	—	—	—	—	(507)
Net loss	—	—	—	—	(173,085)	—	—	(2,133)	(175,218)
Balance at December 31, 2024	124,655	$217	$1,846,843	$4,137	$(1,798,608)	—	$—	$3,486	$56,075
Stock-based compensation	—	—	16,027	—	—	—	—	—	16,027
Exercise of stock options	353	—	2,619	—	—	—	—	—	2,619
Common stock - restricted stock units vesting	1,128	1	—	—	—	—	—	—	1
Common stock issued	11,926	12	241,375	—	—	—	—	—	241,387
Foreign currency translation adjustments	—	—	—	(400)	—	—	—	—	(400)
Unrealized gains on available-for-sale securities	—	—	—	653	—	—	—	—	653
Net income (loss)	—	—	—	—	370,445	—	—	(2,582)	367,863
Balance at March 31, 2025	$138,062	$230	$2,106,864	$4,390	$(1,428,163)	—	$—	$904	$684,225
Stock-based compensation	—	—	13,043	—	—	—	—	—	13,043
Exercise of stock options	36	—	223	—	—	—	—	—	223
Common stock - restricted stock units vesting	46	—	—	—	—	—	—	—	—
Foreign currency translation adjustments	—	—	—	91	—	—	—	—	91
Unrealized gains on available-for-sale securities	—	—	—	876	—	—	—	—	876
Net loss	—	—	—	—	(175,241)	—	—	(3,411)	(178,652)
Balance at June 30, 2025	$138,144	$230	$2,120,130	$5,357	$(1,603,404)	—	$—	$(2,507)	$519,806

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.